NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Price Target & More

$2.40 -0.02 (-0.83 %)
(As of 04/20/2018 12:06 PM ET)
Previous Close$2.42
Today's Range$2.35 - $2.42
52-Week Range$1.55 - $5.75
Volume129,073 shs
Average Volume436,664 shs
Market Capitalization$122.16 million
P/E Ratio-2.20
Dividend YieldN/A
Beta2.42

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Debt-to-Equity Ratio-0.31%
Current Ratio4.64%
Quick Ratio4.57%

Price-To-Earnings

Trailing P/E Ratio-2.20
Forward P/E Ratio-2.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.99 million
Price / Sales15.29
Cash FlowN/A
Price / CashN/A
Book Value($0.73) per share
Price / Book-3.29

Profitability

EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-644.25%
Return on EquityN/A
Return on Assets-63.41%

Miscellaneous

Employees41
Outstanding Shares50,900,000

How to Become a New Pot Stock Millionaire

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals (NASDAQ:ACRX) issued its quarterly earnings data on Thursday, March, 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.20). The specialty pharmaceutical company earned $0.74 million during the quarter, compared to the consensus estimate of $2.90 million. View AcelRx Pharmaceuticals' Earnings History.

What price target have analysts set for ACRX?

7 equities research analysts have issued 1 year target prices for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.40 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder, Chief Medical Officer and Director (Age 55)
  • Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
  • Mr. Vincent J. Angotti, CEO & Director (Age 50)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

Media stories about ACRX stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.04 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 46.33 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.40.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $122.16 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for AcelRx Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 125.00%. The high price target for ACRX is $8.00 and the low price target for ACRX is $2.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.572.57
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.40$5.40$6.8333$7.6667
Price Target Upside: 125.00% upside200.00% upside279.63% upside260.78% upside

AcelRx Pharmaceuticals (NASDAQ:ACRX) Consensus Price Target History

Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
10/13/2017Piper JaffrayReiterated RatingHold$2.00N/AView Rating Details
10/13/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$6.00 -> $5.00N/AView Rating Details
10/13/2017Jefferies GroupDowngradeBuy -> HoldN/AView Rating Details
10/12/2017Roth CapitalSet Price TargetBuy$8.00N/AView Rating Details
8/9/2017Stifel NicolausUpgradeHold -> BuyHighView Rating Details
8/1/2017CowenReiterated RatingHoldHighView Rating Details
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings History and Estimates Chart

Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.24)($0.24)($0.24)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181($0.30)($0.30)($0.30)

AcelRx Pharmaceuticals (NASDAQ ACRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018Q4 2017($0.20)($0.20)$2.90 million$0.74 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.26)($0.28)$2.46 million$1.49 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.28)($0.29)$2.63 million$2.66 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.28)($0.34)$2.36 million$3.11 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.23)($0.21)$3.05 million$6.44 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.25)$2.89 million$1.60 millionViewN/AView Earnings Details
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
5/2/2016Q1 2016($0.22)($0.22)$2.05 million$3.03 millionViewN/AView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)$0.30 million$1.92 millionViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)$0.40 million$0.18 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.33)($0.32)$0.23 millionViewN/AView Earnings Details
11/10/2014Q4 2014($0.33)($0.32)$4.95 million$4.83 millionViewN/AView Earnings Details
8/11/2014Q214($0.27)($0.34)$0.20 million$0.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)$0.28 million$0.10 millionViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)$0.40 million$0.55 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.4070 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.26)($0.34)$0.68 million$0.94 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.39)($0.41)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.39)($0.35)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.35)($0.36)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.39)($0.33)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.34)($0.30)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.32)($0.25)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.22)($0.30)ViewN/AView Earnings Details
3/24/2011Q4 2010($5.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AcelRx Pharmaceuticals (NASDAQ:ACRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 9.20%
Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Mark G EdwardsDirectorBuy30,000$1.90$57,000.00150,000View SEC Filing  
11/13/2017Raffi AsadorianCFOBuy5,000$1.94$9,700.0012,000View SEC Filing  
10/2/2017Lawrence G HamelInsiderSell10,161$5.29$53,751.6916,379View SEC Filing  
9/11/2017Raffi AsadorianCFOBuy7,000$3.24$22,680.007,000View SEC Filing  
8/24/2017Mark G EdwardsDirectorBuy5,000$3.02$15,100.00115,200View SEC Filing  
8/24/2017Vincent J AngottiCEOBuy15,000$3.00$45,000.0015,000View SEC Filing  
8/22/2017Pamela P. PalmerInsiderBuy10,000$2.95$29,500.00View SEC Filing  
6/19/2017Life Sciences Maste PerceptiveMajor ShareholderSell875,000$2.40$2,100,000.00View SEC Filing  
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.5650,000View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00105,000View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AcelRx Pharmaceuticals (NASDAQ ACRX) News Headlines

Source:
DateHeadline
$780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter$780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM
-$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter-$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 18 at 8:32 AM
Pharmacokinetics of AcelRx Pharmas sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarketPharmacokinetics of AcelRx Pharma's sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarket
seekingalpha.com - April 18 at 8:16 AM
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored SettingAcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
finance.yahoo.com - April 18 at 8:16 AM
Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIABlog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
finance.yahoo.com - April 18 at 8:16 AM
AcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngineAcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM
AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2
seekingalpha.com - April 16 at 8:15 AM
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
finance.yahoo.com - April 16 at 8:15 AM
AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngineAcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM
AcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by CowenAcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 14 at 11:48 AM
AcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel NicolausAcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - April 12 at 12:29 AM
AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from AnalystsAcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 5:43 PM
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in EuropeAcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
finance.yahoo.com - April 11 at 5:32 PM
AcelRx Pharmaceuticals (ACRX) Upgraded to Sell by ValuEngineAcelRx Pharmaceuticals (ACRX) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - April 8 at 7:34 PM
PDL BioPharma to Present at the HC Wainwright Global Life Sciences ConferencePDL BioPharma to Present at the HC Wainwright Global Life Sciences Conference
www.prnewswire.com - April 3 at 5:35 PM
AcelRx Pharmaceuticals (ACRX) Expected to Post Earnings of -$0.24 Per ShareAcelRx Pharmaceuticals (ACRX) Expected to Post Earnings of -$0.24 Per Share
www.americanbankingnews.com - April 1 at 7:23 AM
AcelRx announces appointment of John Saia as General CounselAcelRx announces appointment of John Saia as General Counsel
finance.yahoo.com - March 27 at 8:27 AM
When Can We Expect A Profit From AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?When Can We Expect A Profit From AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?
finance.yahoo.com - March 21 at 8:47 AM
Technical Perspectives on Medical Equipment Stocks -- Accuray, AcelRx Pharma, Aethlon Medical, and CHF Solutions - PR Newswire (press release)Technical Perspectives on Medical Equipment Stocks -- Accuray, AcelRx Pharma, Aethlon Medical, and CHF Solutions - PR Newswire (press release)
www.prnewswire.com - March 20 at 8:27 AM
Edited Transcript of ACRX earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of ACRX earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:16 AM
AcelRx Pharmaceuticals Inc (ACRX) Receives Consensus Rating of "Hold" from BrokeragesAcelRx Pharmaceuticals Inc (ACRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 5:30 PM
 Analysts Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $780,000.00 Analysts Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $780,000.00
www.americanbankingnews.com - March 17 at 8:38 AM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) to Announce -$0.24 EPSZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) to Announce -$0.24 EPS
www.americanbankingnews.com - March 15 at 3:10 AM
AcelRx Pharmaceuticals Inc (ACRX) to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group ForecastsAcelRx Pharmaceuticals Inc (ACRX) to Post Q1 2018 Earnings of ($0.24) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 12 at 2:50 AM
Pre-Open Movers 03/09: (PDLI) (ACRX) (ECYT) Higher; (AUTO) (VNRX) (BIG) Lower (more...) - StreetInsider.comPre-Open Movers 03/09: (PDLI) (ACRX) (ECYT) Higher; (AUTO) (VNRX) (BIG) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 10 at 8:21 AM
After-Hours Stock Movers 03/08: (PDLI) (ACRX) (UNFI) Higher; (AUTO) (VNRX) (FNSR) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 03/08: (PDLI) (ACRX) (UNFI) Higher; (AUTO) (VNRX) (FNSR) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 9 at 8:19 AM
FDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month - NasdaqFDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month - Nasdaq
www.nasdaq.com - March 9 at 8:19 AM
26 Stocks Moving In Fridays Pre-Market Session - Benzinga26 Stocks Moving In Friday's Pre-Market Session - Benzinga
www.benzinga.com - March 9 at 8:19 AM
AcelRx Pharmaceuticals (ACRX) CEO Vince Angotti on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaAcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 8:19 AM
AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial ResultsAcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 8 at 6:45 PM
AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018AcelRx announces receipt of Type A FDA meeting minutes and plans to resubmit the DSUVIA New Drug Application in Q2 2018
finance.yahoo.com - March 8 at 6:45 PM
Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
finance.yahoo.com - March 7 at 6:35 PM
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor ... - PR Newswire (press release)AcelRx Pharmaceuticals to Participate at Three Upcoming Investor ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:17 AM
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in MarchAcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March
finance.yahoo.com - March 5 at 8:17 AM
Analyzing Stemline Therapeutics (STML) and AcelRx Pharmaceuticals (ACRX)Analyzing Stemline Therapeutics (STML) and AcelRx Pharmaceuticals (ACRX)
www.americanbankingnews.com - March 2 at 1:39 PM
AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results ... - PR Newswire (press release)AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results ... - PR Newswire (press release)
www.prnewswire.com - March 2 at 8:15 AM
AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results Conference Call and Webcast on Thursday, March 8th, 2018AcelRx Pharmaceuticals to Hold Annual 2017 Financial Results Conference Call and Webcast on Thursday, March 8th, 2018
finance.yahoo.com - March 2 at 8:15 AM
 Brokerages Expect AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million Brokerages Expect AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million
www.americanbankingnews.com - February 28 at 11:36 AM
AcelRx Pharmaceuticals Inc (ACRX) Given Average Rating of "Hold" by BrokeragesAcelRx Pharmaceuticals Inc (ACRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 20 at 5:32 PM
AcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare ConferenceAcelRx Pharmaceuticals to Present at 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 16 at 8:17 AM
Jefferies Group Weighs in on AcelRx Pharmaceuticals Incs FY2019 Earnings (ACRX)Jefferies Group Weighs in on AcelRx Pharmaceuticals Inc's FY2019 Earnings (ACRX)
www.americanbankingnews.com - February 15 at 3:10 PM
Brokers Offer Predictions for AcelRx Pharmaceuticals Incs FY2022 Earnings (ACRX)Brokers Offer Predictions for AcelRx Pharmaceuticals Inc's FY2022 Earnings (ACRX)
www.americanbankingnews.com - February 14 at 4:14 PM
AcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of "Hold" from AnalystsAcelRx Pharmaceuticals Inc (ACRX) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 26 at 5:38 PM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $2.90 MillionZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 25 at 3:44 AM
AcelRx Pharmaceuticals (ACRX) Downgraded to "Hold" at Zacks Investment ResearchAcelRx Pharmaceuticals (ACRX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 23 at 5:28 PM
AcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" at Zacks Investment ResearchAcelRx Pharmaceuticals (ACRX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 16 at 5:24 PM
Zacks Investment Research Downgrades AcelRx Pharmaceuticals (ACRX) to HoldZacks Investment Research Downgrades AcelRx Pharmaceuticals (ACRX) to Hold
www.americanbankingnews.com - January 15 at 4:28 PM
Zacks: Brokerages Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 MillionZacks: Brokerages Anticipate AcelRx Pharmaceuticals Inc (ACRX) Will Post Quarterly Sales of $2.90 Million
www.americanbankingnews.com - January 8 at 4:40 PM
Zacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per ShareZacks: Analysts Expect AcelRx Pharmaceuticals Inc (ACRX) Will Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - January 6 at 11:28 AM
How to Short a Stock - BenzingaHow to Short a Stock - Benzinga
www.benzinga.com - January 4 at 5:20 AM

SEC Filings

AcelRx Pharmaceuticals (NASDAQ:ACRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AcelRx Pharmaceuticals (NASDAQ:ACRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AcelRx Pharmaceuticals (NASDAQ ACRX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.